Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BKHM dropping like a rock after the announcement of a 25.5 mil private placement. Any thoughts on this? Why the panic?
Thanks,
Wahz, Are you concened about NENG??? Do you still like it long term?
Thanks
Zeev, What's your target for HAUP? Do you see any pullbacks before moving higher?
Thanks
Anybody been watching ARBA. Looks real promising after the reverse split. Usually rS don't work out in favor of the investor.
Wahz, Do you see any positives to the reverse split coming in BKHM? Some on other boards are saying its not technically a rs.
Thanks,
ARBA up $9 today
1 for 6 reverse split in effect. Now trading as ARBAD
Bull, Just saw your post on ARBA. What's you take on the reverse split?
Thanks
TLGB= LOTS OF PAIN!!. Is it worth holding or taking the loss?
Whats your take long term?
Thanks
What happened to MANU? I didn't see any news. Anybdy know what caused the drop?
Are you still in ITXC? Is this good for ITXC stockholders?
Thanks,
ARBA is looking to do a 5/1 reverse split in June does this worry anybody? It usually isn't good for shareholders. Has it been dropped from the list?
ITXC--Sorry it took me`so long to reply I was out of town. That was taken off a stock report on Raging Bull website. I am surprised nobody else commented on it. Is it off the list??
Did everybody sell??
Any comments on this reverse merger?? ITXC: Reit Underperform - We reiterate our UNDERPERFORM rating on ITXC Corp. (ITXC). After spending substantial capital constructing a global VoIP platform and building a global distribution channel, the company has failed to make the leap up the value stack to attack end user recurring revenue streams and capture enough margin to become self-sustaining. Given continued weak results, ITXC has agreed to sell its business to Teleglobe in a reverse merger transaction, whereby its shareholders will receive 28% of the combined $1.1BN run rate global carrier. Under the proposed deal, investors face integration risk, likely pressure from customers rerating their contracts, pricing pressure from restructured competitors like MCI and Global Crossing, lack of FCF+ until 2H04, and a weak balance sheet with roughly $100MM in debt. Further, we believe international settlement rates are collapsing, eliminating the arbitrage opportunity provided by the ITXC/Teleglobe plan and calling into question a wholesale-only strategy.
Zeev, Haup hit your $8 target are you still looking for a pullback before going on to $14?
Thanks,
Zeev, HAUP doing well today. Are you still looking for $8.00.
Thanks
Researchers: Stem Cells May Cure Baldness
By PAUL ELIAS, AP Biotechnology Writer
Sun Mar 14, 3:38 PM ET
SAN FRANCISCO - Research showing that bald mice can grow hair after being implanted with a type of stem cell could lead to a cure for baldness, a group of scientists says.
The project marks the first time that "blank slate" stem cells were able to induce hair growth, said Dr. George Cotsarelis, a University of Pennsylvania dermatologist and co-author of the study.
The study was released Sunday on the Web site of the journal Nature Technology in advance of its April publication date.
"We've shown for the first time these cells have the ability to generate hair when taken from one animal and put into another," Cotsarelis said in a telephone interview. "You can envision a process of isolating existing stem cells and re-implanting them in the areas where guys are bald."
The study confirms what scientists suspected for years: hair follicles contain "blank slate" stem cells that give most humans a full head of hair for life.
Although they are called stem cells, they differ from embryonic stem cells, the research on which has sparked a political debate because embryos are destroyed in the process. Embryonic stem cells are created in the first days after conception and give rise to the human body and its more than 200 different types of cells.
Biologists who study hair because of its regenerative qualities said the new study is an important breakthrough. But they cautioned that a baldness cure is still some years away.
"Like with any stem cells, the amount of information needed to get us from a stem to a fully developed organ is a lot," said Stanford University biologist Anthony Oro. "It will require a lot of things to go right and we are still along way off."
Two drugs now on the market, known commercially as Rogaine and Propecia, were first designed to treat hypertension and enlarged prostates but later were discovered to have hair growth as a side effect. Each drug has about $100 million in sales annually.
It's estimated that more than $1 billion is spent each year in the United States combatting baldness, mostly through hair transplants.
Anybody have an outlook for MANU? Does it still looks good long term?
Thamks,
NENG-Some insider selling in the past month. Why would they sell when its down? Are they telling us not to expect news for awhile?
NENG up premarket news pending??
ITXC HAD RECORD FOURTH QUARTER
·FULL YEAR REVENUES INCREASED 26% to $338.4 MILLION
·FULL YEAR MINUTES EXCEEDED 4 BILLION
NENG looking good!! Will it run???
Wow! it looks like this article hit a nerve. Looking forward to your response. Just remember to breathe slowly and stay calm:)
Maine, Interesting article in Wisconsin paper today and GERN has tie's to University of Wisconsin. Do you think this can help or hurt GERN?
State's stem cell limelight may fade
Other places, notably California, are trying to pursue the research
Posted: Feb. 14, 2004
Wisconsin's head start in stem cell research could fade quickly if other states succeed with bold new biotechnology initiatives of their own.
Researchers and biotechnology companies could flock to California if voters approve a bond proposition there intended to pump $3 billion over 10 years into human embryonic stem cell research.
"It's a huge amount of money," said Barbara Lewis, manager of the Wisconsin Stem Cell Research Program. "There is no question they would become the national leader."
Wisconsin has basked in national and international attention since 1998, when University of Wisconsin-Madison researcher James Thomson became the first to isolate human embryonic master cells. These cells are thought to hold the promise of curing diseases that today are incurable.
Along with inspiring dreams of defeating such maladies as Parkinson's and Alzheimer's, the biotechnology breakthrough also left Wisconsin officials hopeful that companies would bring laboratories and jobs to the state as they sought access to pioneers of this emerging field.
Wisconsin officials are determined not to yield the state's prominent position to other states sharing the same stem cell aspirations.
Ohio, New Jersey and Pennsylvania are among those seeking major life sciences research programs that could strengthen their stem cell work.
More recently, Minnesota Gov. Tim Pawlenty created a bioscience package that would devote millions of dollars to research facilities, tax credits and venture capital in his state. The University of Minnesota, which already has a Stem Cell Institute, recently announced a drive that would expand its work with human embryonic stem cells.
States put up money
The scope of the California proposal is attracting so much attention because it could eclipse all other initiatives.
A coalition that includes Hollywood figures and leading scientists is backing an organization called Californians for Stem Cell Research and Cures. It hopes to present voters with a measure in November that would provide $295 million a year for laboratory projects.
The California campaign has just begun, and it is far from clear whether such an ambitious proposal will be approved in that cash-strapped state.
What is clear is that Wisconsin will face determined competition from states motivated by California's attempt to capitalize on stem cell technology, said Dan Perry, president of the Coalition for the Advancement of Medical Research.
"It's a bold initiative," Perry said from his Washington, D.C., office. "I think it will inspire other states to emulate it, particularly if it is successful at the polls."
Restrictions on federal funds for stem cell research put in place in 2001 make the state funding efforts particularly notable, he said.
"We are dramatically underfunding the potential of this effort," Perry said.
Because they are derived from embryos that are destroyed in the process, stem cells have attracted controversy. Some states have considered legislation restricting the research.
States like California that pass laws in support of stem cell research, and go further to create a pool of funding, stand to gain a tremendous advantage in attracting leading laboratory teams, Perry said.
"Clearly you want to go to a place where you have an infrastructure where your work can flourish and where you are likely to find funding," Perry said.
Wisconsin has leaders
Wisconsin already has leaders in the stem cell field who continue to produce advances that raise hopes for treating diabetes and damaged hearts, said Andrew Cohn, government and public affairs manager for the Wisconsin Alumni Research Foundation.
"We have a tremendous head start on a whole variety of states that are now trying to catch up," Cohn said.
At least 30 faculty at the university are actively working with stem cells or moving into the area, according to the university's stem cell research program. The corps of stem cell researchers swells to at least 150 when counting assistants and other staff. These projects attract an estimated $15 million to $20 million a year in grants from federal agencies, research foundations and other private donors.
The WiCell Research Institute, an affiliate of the foundation, has about a dozen more staff members devoted to stem cell work. The institute has distributed stem cells to 150 other research institutions and conducts monthly training sessions on how to work with stem cells.
The foundation, which controls key stem cell patents and oversees technology transfer for UW-Madison, continues to view stem cells as one of the most important innovations in its portfolio. Commercial interest in licensing the technology continues to grow.
No biotechnology companies involved in stem cells have established new labs or offices in Madison, although that remains a likely prospect as the research moves beyond basic science and closer to developing treatments, Cohn said.
More investments to come
Pioneering work with stem cells is an example of the type of internationally renowned research and development that promises to bring Wisconsin high-growth, high-wage businesses, said Cory Nettles, secretary of the Wisconsin Department of Commerce.
"We have significant opportunities to lure additional businesses to Wisconsin that would start up in the biotechnology space," Nettles said.
Wisconsin continues making the investments necessary to maintain its momentum with stem cell research and biotechnology in general, Nettles said.
The $317 million Biostar initiative, which is building new labs necessary to keep and attract top researchers, continues to progress at UW-Madison, Nettles said.
When Gov. Jim Doyle meets with business people and investors from around the world, they often are the first to bring up Wisconsin's prominent stem cell successes, Nettles said.
"It put us on the map in a big way," Nettles said. "We are going to do everything we can to build on that foundation."
GERN news. Small Interfering RNA (siRNA) Conference & Exposition to Take Place April 19-21, 2004 in San Diego, CA
PR Newswire - February 11, 2004 12:00
SAN DIEGO, Feb 11, 2004 /PRNewswire via COMTEX/ -- Small interfering RNAs (siRNAs) have gained much attention from the biotech and pharmaceutical industries in recent years. Due to their powerful ability in selective gene silencing, siRNAs hold great commercial prospects not only as a handy research tool, but also as a new approach for effective therapeutics. The "2nd Annual siRNA in Drug Discovery & Development" conference and exposition, organized by Strategic Research Institute, is scheduled to take place April 19-21, 2004 at the Marriott Del Mar in San Diego, CA. The upcoming conference will feature senior-level management and research scientists from major pharmaceutical and biotech companies as well as siRNA/RNAi therapeutic, reagent, functional genomic, and other RNAi companies.
The conference agenda is divided into the following sections:
- siRNA/RNAi in Target Validation & Therapeutics
- Antisense and Other Oligonucleotide Therapeutics
- In Vivo Monitoring in RNAi, Protein Profiling & Nucleic Acid Delivery
- Intellectual Property Landscape in RNAi
- Strategic Alliances and Partnering Opportunities to Build a Successful
RNAi Business
There will be over 30 different presentations represented by 38 different companies at the upcoming event. Some of the companies participating include Alnylam Pharmaceuticals, Inc., Ambion, Amgen, Archemix, Avocel, Inc., Beckman Research Institute of the City of Hope, Cyntellect, Cytrx Corporation, Dharmacon, Exelixis, Foley & Lardner, Genomics Institute of the Novartis Research Foundation, Geron Corporation, Harvard Medical School, Intradigm, Invitrogen, ISIS Pharmaceuticals, Lawrence Berkeley National Laboratory, Massachusetts Institute of Technology, McDonnell, Boehnen, Hulbert & Berghoff, Nucleonics, Inc., Pierce Biotechnology, Promega, Rosetta Inpharmatics, Sirna Therapeutics, University of California San Diego, Xenogen, Zygogen and many more.
To request a copy of the agenda and schedule in PDF format, please contact Glenn Pascual at gpascual@srinstitute.com or call 212.967.0095, ext. 245. and include name, title, company and mailing address.
To register as an exhibitor or inquire about sponsorship opportunities, please contact Kellie Swanstrom at kswanstrom@srinstitute.com
Current Sponsors and Exhibitors signed up currently include Sirna Therapeutics, Xenogen Corporation, Archemix, Ambion, Promega, Proligo, and Dharmacon.
To inquire on how to become a media partner, please contact Cheryl Kahan- Radhuber at ckahan-radhuber@srinstitute.com
SOURCE Strategic Research Institute
Zeev, HAUP doing great today. Are you holding long term and adding on the way up or do you think it will get back to your buy range of 3.90 to 4.25?
Thanks
Zeev, Are you still looking to double under 46 on NVEC?
Zeev, I know you got out of AGM but do you think its risky to stay with it now?
Thanks
Owens Corning Secures Cost Savings With Ariba Spend Management Solutions ( ARBA) .--(BUSINESS WIRE)--Feb. 4, 2004--
A little good news in a falling market.
Zeev, If AGM doesn't bounce here ar you getting out?
Zeev, AGM support seems to be around 26.55 are you planning on holding AGM longer term?
Thanks
Thanks Zeev, I was stopped out of pnra at 43.00. So it turned out great.
Maine, What's your take on the AXYX news? Are you still holding it?
Thanks,
Main, You holding AXYX over the long weekend?
Yes I am but getting nervous. I raised my stop to 39.38. I hope your right but not sure I'll hold over the long weekend.
Zeev, If and when the market corrects do you have any OB?
Thanks,
COCO-Lehman Bro raising our 12-month price target on Corinthian Colleges` shares this morning from $71 to $73, based on 28x our CY`05 EPS estimate of $2.63.
COCO moving up. Do you still have it? Any target?
Thanks
Jerry, Do you trade ONNN Semi? Chart looks pretty good?
Zeev, You planning on getting back into COCO on a pullback? Looks like 50 dma is 57.30 think it will go down that far?
Geron Corp (GERN)$9.80. Rumor that Roche will make a $24 all stock bid for company. Click below to read more about subscribing to the full JAGnotes product. http://www.jagnotes.com/c/23/98.cfm?pagetitle=SubscribeNow Copyright 2003 JAGfn.com All Rights Reserved